Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Insourcing Non-preferred Medical Oncology Drug Clinical Reviews from AIM Effective June 1, 2022 May 04, 2022 Pharmacy

Starting June 1, 2022, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will begin to process clinical reviews for all non-preferred Commercial medical oncology drugs listed in the below charts in-house instead of through AIM. This change applies to non-preferred originator and biosimilar products for Commercial members with the AIM oncology program through Blue Cross NC. This follows a similar process to how our other medical drugs are reviewed at Blue Cross NC.  

Also, we have removed prior authorization from all preferred medical oncology drug products (see charts below) and therefore will not do clinical reviews of these preferred products. We've updated our policies in the drug authorization search tool on the Getting Your Patient's Prescriptions Covered to reflect that change. 

Preferred Bevacizumab Containing Agent(s) (Unrestricted) 

  • Mvasi (bevacizumab-awwb) 
  • Zirabev (bevacizumab-bvzr) 

Non-Preferred Bevacizumab Containing Agent(s) 

  • Avastin (bevacizumab) 

Preferred Rituximab Containing Agent(s) (Unrestricted)

  • Ruxience (rituximab-pvvr)* 
  • Truxima (rituximab-abbs)* 

Non-Preferred Rituximab Containing Agent(s) (Unrestricted) 

  • Rituxan (rituximab) 
  • Riabni (rituximab-arrx) 

Preferred Trastuzumab Containing Agent(s) (Unrestricted) 

  • Kanjinti (trastuzumab-anns) 
  • Ogivri (trastuzumab-dkst) 

Non-Preferred Trastuzumab Containing Agent(s)

  • Herceptin (trastuzumab) 
  • Herzuma (trastuzumab-pkrb) 
  • Ontruzant (trastuzumab-dttb) 
  • Trazimera (trastuzumab-qyyp) 

Preferred Filgrastim Products (Unrestricted) 

  • Nivestym (filgrastim) 
  • Zarxio (filgrastim-sndz) 

Non-Preferred Filgrastim Products

  • Granix (tbo-filgrastim) 
  • Neupogen (filgrastim) 
  • Releuko (filgrastim)  

Preferred Pegfilgrastim Products (Unrestricted)

  • Udenyca (pegfilgrastim-cbqv) 
  • Ziextenzo (pegfilgrastim-bmez) 

Non- Preferred Pegfilgrastim Products

  • Fulphila (pegfilgrastim-jmdb) 
  • Neulasta, Neulasta OnPro (pegfilgrastim) 
  • Nyvepria (pegfilgrastim-apgf) 

 

*Indicated products may still require review for non-oncology related indications, please refer to Getting Your Patient's Prescription Drugs Covered page for more information.

Providers requesting prior authorization for a non-preferred product on or after June 1, 2022, for an applicable Commercial member will need to submit the request through CoverMyMeds instead of through the AIM portal. No action is needed prior to June 1.  

AIM will continue to conduct clinical reviews for all other drugs in the AIM medical oncology program.